Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
Details : Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a USFDA approved fixed dose combination. It is now approved for the treatment of HIV in pregnant adults.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2024
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biktarvy® Shows High Rates of Viral Suppression in HIV Patients with Comorbidities
Details : Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a USFDA approved fixed dose combination. It is being evaluated for the treatment of HIV and Hepatitis B.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 06, 2024
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Lenacapavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Gilead’s Innovative HIV Research Pipeline Aims to Address Unmet Needs and Advance Health
Details : GS-9883 (bictegravir), an HIV type 1 integrase inhibitor in combination with GS-6207 (lenacapavir), a structural capsid protein inhibitor is being evaluated for the treatment of HIV-1-infection.
Brand Name : GS-9883
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 05, 2024
Lead Product(s) : Bictegravir,Lenacapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Expanded Indication for Biktarvy to Treat HIV with Suppressed Viral Loads
Details : Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a USFDA approved fixed dose combination. It got extended approval for HIV with suppressed viral loads, pre-existing resistance.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2024
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Biktarvy is a combination of bictegravir which targets HIV-1 integrase thus inhibiting HIV virus replication, emtricitabine and tenofovir alafenamide which inhibits the activity of the HIV-1 reverse transcriptase resulting in DNA chain termination.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2023
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Biktarvy is a complete HIV treatment that combines three powerful medicines to form the smallest 3-drug, integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 29, 2022
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Biktarvy (bictegravir) is HIV treatment that combines three powerful medicines to form smallest 3-drug, INSTI-based single-tablet regimen available, offering simple once-daily dosing with or without food, with limited drug interaction potential and high ...
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data from ALLIANCE trial evaluating Biktarvy (bictegravir) versus dolutegravir 50 mg (DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, demonstrated the efficacy of both antiretroviral regimens, in adults with HIV/HBV co-infection initiat...
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 28, 2022
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Five-year cumulative outcomes, Biktarvy (bictegravir, emtricitabine, tenofovir, alafenamide) in treatment-naïve people living with HIV, high barrier to resistance, durability, efficacy, and safety in people with HIV who initiated treatment with single-t...
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 21, 2022
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Biktarvy is a complete HIV-1 treatment that combines three powerful medicines to form the smallest 3-drug, integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available, offering simple once-daily dosing with or without food.
Brand Name : Biktarvy
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 11, 2022
Lead Product(s) : Bictegravir,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?